
- Volume 0 0
Lithium Carbonate ER
Roxane Laboratories Inc (Columbus,Ohio) recently announced the approval ofLithium Carbonate Extended ReleaseTablets USP, 450 mg. This product is ABratedto GlaxoSmithKline?s Eskalith CR(lithium carbonate) 450 mg. LithiumCarbonate Extended Release Tablets areindicated for the treatment of manicepisodes of manic?depressive illness.Maintenance therapy prevents or diminishesthe intensity of subsequentepisodes in those manic?depressivepatients with a history of mania. Thetablets may produce a normalization ofsymptomatology within 1 to 3 weeks. Formore information, visit www.roxane.com.
Articles in this issue
over 22 years ago
Interface Speeds Up Prescription Fillingover 22 years ago
New Technologies Top Surveyover 22 years ago
Partnership Addresses Packaging Solutionsover 22 years ago
PDX Software Gets High Marksover 22 years ago
Polar Powder Cold Pak with Magnetic Therapyover 22 years ago
Seal•ONover 22 years ago
SaltAire Sinus Reliefover 22 years ago
Zim's Crack Creme Hand Sanitizerover 22 years ago
CoroWise Plant Sterolsover 22 years ago
Culturelle




































































































































